These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
192 related items for PubMed ID: 35378215
1. PD1 CD44 antiviral peptide as an inhibitor of the protein-protein interaction in dengue virus invasion. Recalde-Reyes DP, Rodríguez-Salazar CA, Castaño-Osorio JC, Giraldo MI. Peptides; 2022 Jul; 153():170797. PubMed ID: 35378215 [Abstract] [Full Text] [Related]
2. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection. Panya A, Sawasdee N, Junking M, Srisawat C, Choowongkomon K, Yenchitsomanus PT. Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143 [Abstract] [Full Text] [Related]
3. Peptide inhibitors of dengue virus and West Nile virus infectivity. Hrobowski YM, Garry RF, Michael SF. Virol J; 2005 Jun 01; 2():49. PubMed ID: 15927084 [Abstract] [Full Text] [Related]
4. Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication. Abdul Ahmad SA, Palanisamy UD, Tejo BA, Chew MF, Tham HW, Syed Hassan S. Virol J; 2017 Nov 21; 14(1):229. PubMed ID: 29162124 [Abstract] [Full Text] [Related]
5. Peptide inhibitors against dengue virus infection. Panya A, Bangphoomi K, Choowongkomon K, Yenchitsomanus PT. Chem Biol Drug Des; 2014 Aug 21; 84(2):148-57. PubMed ID: 24612829 [Abstract] [Full Text] [Related]
6. Antiviral Activity of Rosmarinic Acid Against Four Serotypes of Dengue Virus. Panchal R, Ghosh S, Mehla R, Ramalingam J, Gairola S, Mukherjee S, Chowdhary A. Curr Microbiol; 2022 May 25; 79(7):203. PubMed ID: 35612625 [Abstract] [Full Text] [Related]
8. Development of novel antiviral peptides against dengue serotypes 1-4. Lee MF, Anasir MI, Poh CL. Virology; 2023 Mar 25; 580():10-27. PubMed ID: 36739680 [Abstract] [Full Text] [Related]
9. In silico design of peptide inhibitors for Dengue virus to treat Dengue virus-associated infections. Ajmal A, Shahab M, Waqas M, Zheng G, Zulfat M, Bin Jardan YA, Wondmie GF, Bourhia M, Ali I. Sci Rep; 2024 Jun 07; 14(1):13130. PubMed ID: 38849372 [Abstract] [Full Text] [Related]
11. Glycyrrhizic Acid Derivatives Bearing Amino Acid Residues in the Carbohydrate Part as Dengue Virus E Protein Inhibitors: Synthesis and Antiviral Activity. Hour MJ, Chen Y, Lin CS, Baltina LA, Kan JY, Tsai YT, Kiu YT, Lai HC, Baltina LA, Petrova SF, Lin CW. Int J Mol Sci; 2022 Sep 07; 23(18):. PubMed ID: 36142222 [Abstract] [Full Text] [Related]
12. Repurposing of therapeutic antibodies against dengue virus envelope protein receptor binding domain. Chaudhuri D, Majumder S, Datta J, Giri K. Arch Microbiol; 2024 Jun 20; 206(7):312. PubMed ID: 38900285 [Abstract] [Full Text] [Related]
13. In vitro analysis of synthetic peptides in blocking the entry of dengue virus. John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P. Virus Res; 2019 Jan 15; 260():142-150. PubMed ID: 30508603 [Abstract] [Full Text] [Related]
14. Innate immunity to dengue virus infection and subversion of antiviral responses. Green AM, Beatty PR, Hadjilaou A, Harris E. J Mol Biol; 2014 Mar 20; 426(6):1148-60. PubMed ID: 24316047 [Abstract] [Full Text] [Related]
15. Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells. Wu DW, Mao F, Ye Y, Li J, Xu CL, Luo XM, Chen J, Shen X. Acta Pharmacol Sin; 2015 Sep 20; 36(9):1126-36. PubMed ID: 26279156 [Abstract] [Full Text] [Related]
17. Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins. Zidane N, Dussart P, Bremand L, Bedouelle H. BMC Infect Dis; 2013 Jul 01; 13():302. PubMed ID: 23815496 [Abstract] [Full Text] [Related]
18. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. van Cleef KW, Overheul GJ, Thomassen MC, Kaptein SJ, Davidson AD, Jacobs M, Neyts J, van Kuppeveld FJ, van Rij RP. Antiviral Res; 2013 Aug 01; 99(2):165-71. PubMed ID: 23735301 [Abstract] [Full Text] [Related]
19. Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus. Anasir MI, Ramanathan B, Poh CL. Viruses; 2020 Mar 26; 12(4):. PubMed ID: 32225021 [Abstract] [Full Text] [Related]
20. A novel flavanone derivative inhibits dengue virus fusion and infectivity. Srivarangkul P, Yuttithamnon W, Suroengrit A, Pankaew S, Hengphasatporn K, Rungrotmongkol T, Phuwapraisirisan P, Ruxrungtham K, Boonyasuppayakorn S. Antiviral Res; 2018 Mar 26; 151():27-38. PubMed ID: 29360474 [Abstract] [Full Text] [Related] Page: [Next] [New Search]